1 American Society of Cytopathology Core Curriculum in Molecular Biology
2 American Society of Cytopathology Core Curriculum in Molecular Biology Chapter 1 Molecular Basis of Cancer Molecular Oncology Keisha N. Brooks, MS, CT, MB(ASCP) University of Tennessee Health Science Center Memphis, Tennessee
3 What Are Tumors? Brought Tumors are the result of a disease process in which a single cell proliferates abnormally, resulting in an accumulation of progeny cells. The Genetic Basis of Human Cancer. Vogelstein B and Kinzler KW (Editors). McGraw Hill, New York, 1998.
4 What Is Cancer? Cancer is a collection of diseases characterized by the uncontrolled growth and spread of abnormal cells. Cancer Facts and Figures American Cancer Society
5 Comparison of Benign and Malignant Neoplasms Benign Gross appearance Smooth margins, encapsulated Center resilient, soft, viable Malignant Gross appearance Rough margins, no capsule Firm center, focal necrosis Microscopic pattern Resembles normal, welldifferentiated compressed adjacent tissue Intact basement membrane Cells and nuclei are normal size/shape Microscopic pattern Poorly differentiated Invasive to adjacent tissues Disrupted basement membranes Cells and nuclei are large/irregular
6 Comparison of Benign and Malignant Neoplasms (cont.) Benign Slow growth rate No metastatic disease Produces local effects Malignant Rapid growth rate Metastases are common Can cause local and/or distant pathophysiological effects
7 Cancer Is a Genetic Disease Cancer is a disease of genes or gene regulation that begins in a single cell and results in the loss of control of cell growth. Any cell type can become malignant. Carcinogenesis can result from acquired and/or inherited genetic abnormalities.
8 Environmental Chemical Radiation(UV) Infectious Viruses(EBV, HPV) Hereditary Germline genetic defects Brought Cancer: A Group of Multifactorial/Polygenic Diseases
9 Cancer Pathogenesis: A Multi step Process Normal epithelial cell Malignant transformation Tumorigenesis Carcinoma Multi step Cancer Induction with Chemicals Occurs in Definable Stages Initiation Promotion Progression
10 Clonal Basis of Cancer Development Tumors arise from a single ancestral cell that has accumulated critical initiating mutations (genetic changes) In some cases, these mutations (genetic changes) are present in all cells (genetic predisposition). Multiple mutations are needed for tumor formation. The number of mutations is independent of the tumor type.
11 Carcinogenesis Is a Multistage Process Chemical radiation virus Defects in cellular differentiation Defects in growth control Resistance to cytotoxicity Genetic change Selective clonal expansion Genetic change Normal Cell Initiated Cell Preneoplastic Lesion Malignant Tumor Activation of Protooncogenes Inactivation of Tumor Suppressor Genes
12 Oncology Markers Used to assess genetic mutations for an individual patient s tumor (a.k.a. tumor profiling) Helps guide clinicians in selecting the most appropriate therapeutic regimen Development of molecular pharmacogenetics is result in new prognostic indicators being used for the assessment of individual tumors
13 Review: Classification of Neoplasms Neoplasia: 2 broad groups Solid tumors Designated according to tissue of origin Carcinoma (epithelial) Sarcoma (bone, cartilage, muscle, blood vessels, fat) Teratocarcinoma: multiple cell types Hematological malignancies Arise from white blood cells Leukemia Lymphoma» Hodgkin s disease» Non Hodgkin s lymphoma» Plasma cell neoplasms
14 Cancer: Caused by Nonlethal Genetic Mutations Affecting Certain Genes. Brought Oncogenes, as proto oncogenes, normally promote cell division or cell survival. Support cell survival by inhibiting apoptosis 100 oncogenes identified in human genome Oncogene mutations are usually a gain of function Results from amplification or translocation of DNA regions containing the genes
15 Cancer: Caused by Nonlethal Genetic Mutations Affecting Certain Genes. Tumor suppressors: genes normally arrest cell division Include factors controlling transcription or translation of genes Repairs DNA damage and promotes apoptosis Counteracts movement of cell from G1 to S or G2 to M phase of mitosis G1 check point and G2 checkpoint More that 30 tumor suppressor genes currently identified Tumor suppressor gene mutations are usually a loss of function Results in inactivation tumor suppressor gene products Occur through deletions, translocations, or mutation of the gene
16 Proto oncogene and Tumor Suppressor Gene Products Regulate Cell Proliferation Regulated by tumor suppressor genes Normal Proto oncogene products Cell growth and proliferation Loss or mutation of tumor suppressor genes Cancer Oncogenes Abnormal cell growth and proliferation Neoplasia
17 The Cell Cycle
18 Molecular Detection of Disease Brought Targets: Tissue specific markers (antigens, gene rearrangements) Disease specific markers (translocations, point mutations, polymorphisms in tumor suppressor or oncogenes) Viruses Methods: Hybridization, blotting (Southern Blot) Standard PCR, RT PCR, electrophoresis Real time PCR with gene or patient specific probes
19 Gene and Chromosome Abnormalities Observed in Cancer Brought Gene mutations (oncogenes, tumor suppressor genes) Chromosome structural abnormalities (translocations, deletions, insertions) Chromosome number abnormalities (aneuploidy, polysomy)
20 Ras Point Mutations Most common oncogene abnormality in human cancers ras genes code for membrane associated proteins that trigger cell division Mutated ras proteins are stuck in the ON position
21 Molecular Abnormalities in Solid Tumors, K-ras Brought The Kirsten rat sarcoma viral oncogene (K ras) encodes a key component of cell signaling. Mutations in K ras are the most common oncogene mutations in cancer. K ras mutations are associated with tumor malignancy and may affect response to some therapies. K ras gene mutations are detected by PCR or direct sequencing.
22 K-ras Mutations K ras mutations Colorectal tumors: GI tumors with mutations in K ras have been shown to be more likely to reoccur. The proto oncogene recognized as mutated most commonly in endometrial carcinoma is K ras (10 30%).
23 Cellular Proto oncogenes Activated by Gene Amplification c myc Leukemias, breast, stomach, lung, and colon carcinomas, neuroblastomas, and glioblastomas c K ras Lung, ovarian, and bladder carcinomas PRAD 1 Breast and squamous cell carcinomas mdm2 Sarcomas
24 Cellular Proto oncogenes Activated by Chromosomal Translocation Producing Aberrant Protein Expression c myc Burkitt s lymphoma and other B cell lymphoma PRAD 1 Chronic B cell leukemia bcl2 Follicular B cell lymphoma
25 Molecular Abnormalities in Solid Tumors, HER2/neu The HER2/neu gene encodes one of a family of human epidermal growth factor receptors (EFGR). This gene is frequently amplified in breast cancer cells, resulting in increased amounts of HER2 cell surface protein. HER2 expressing tumors are sensitive to herceptin, a monoclonal antibody therapy. HER2 protein is detected by immunohistochemistry (IHC). HER2/neu gene amplification is detected by fluorescence in situ hybridization (FISH), cytogenetics, and immunostaining
26 Her2/neu Brought 25% breast cancer patients have tumors with overexpressed Her2/neu gene Generally associated with a poor prognosis; patients eligible for herceptin treatment IHC for Her2/neu often difficult to discern due to weak positive signals or background staining Large percentage of tumors considered positive by IHC for Her 2 show no gene amplification; therefore, IHC produce false positive results
27 Brought Differences in Interpretation: HER-2 Assessment by FISH and IHC FISH High amplification Low amplification Normal IHC Negative/0
28 Her2/neu Brought FISH testing may have a sensitivity and specificity of % for detecting over expression of the Her2/neu gene Enhances the opportunity for more effective therapeutic triage * Available with Ventana (ISH) and Vysis, Inc. (PathVision) Ventana Benchmark (ISH) *Single Colormetric marker Vysis (Pathvision) *Dual Colormetric marker
29 Her 2 Neu PCR also available for testing of Her2/neu using Roche Light Cycler Chromogenic ISH assays for Her2/neu (for use with bright field microscopy) are currently under development and offer promising options to fluorescent microscopic interpretation
30 Tumor Suppressor Genes Code for proteins that down regulate cell division. Recessive acting/loss of function Expression inhibits cancer formation Knudson s two hit hypothesis of cancer development: Both alleles are inactivated by mutation or deletion.
31 Tumor Suppressor Genes or Their Protein Products Are Inactivated in Cancer One gene copy is mutated, while the other is lost (allelic deletion or loss of heterozygosity). Most mutations are acquired (somatic). Some are inherited (Knudson s hypothesis). First hit (mutation) is inherited; second hit results from somatic mutation or loss (chromosomal deletion).
32 Tumor Suppressor Protein Functions Regulation of cell proliferation (cell cycle progression) Contact inhibition (cellular growth control) Signal transduction (cell membrane to nucleus) Gene expression (nuclear transcription factors) Cell cycle checkpoints ( guardians of the genome) DNA repair ( caretakers of the genome)
33 Tumor Supressor: p53 Located on human chromosome 17 Represents the most commonly mutated gene among all human cancers. Normal (wild type) p53 protein localizes to the nucleus and has a short half life.
34 p53 (cont.) Mutation results in abnormal accumulation of protein in the nucleus. After DNA damage, p53 functions to delay the G1/S cell cycle transition, enabling DNA repair. Wild type p53 protein induces apoptosis.
35 Inherited Breast Cancer Risk BRCA1 and BRCA2 are tumor suppressor genes encoding proteins that participate in DNA repair. Inherited mutations in BRCA1 or BRCA2 significantly increase risk of breast cancer at an early age. Most mutations are detected by direct sequencing of both genes.
36 Hereditary Nonpolyposis Colorectal Carcinoma Hereditary nonpolyposis colorectal carcinoma (HNPCC) accounts for about 5% of colon cancer. Also known as Lynch Syndrome HNPCC is the most common form of hereditary colon cancer. HNPCC is associated with mutations in genes encoding components of the mismatch repair system (MMR)
37 Molecular Detection of Leukemia and Lymphoma Targets: Brought Antibodies, gene rearrangements, translocations, point mutations, polymorphisms, viruses Methods: Hybridization, blotting Standard PCR, RT PCR, electrophoresis Real time PCR with gene or patient specific probes
38 Gene Rearrangements (GR) Gene rearrangements are normal events that occur in lymphocytes. Antibody genes [immunoglobulin heavy chain genes, immunoglobulin light chain genes (, )] and T cell receptor genes (,,, ) rearrange. Rearrangement occurs independently in each cell.
39 Gene Rearrangements Gene rearrangements may be used to detect leukemias and lymphomas arising from cells that have rearranged their immunoglobulin (Ig) or T cell receptor (TCR) genes.
40 Lymphomas and Kappa Lambda Detection of Kappa and Lambda light chain mrna in plasma cells and B lymphocytes Each immunoglobulin molecule contains either two Copies of Kappa or lambda light chains K/L ratio 2:1 = Reactive Lymphoid Hyperplasia K/L or L/K ratio 3:1 or greater: B cell Lymphoma * Ventana Benchmark (ISH)
41 Lymphomas One of the oldest tests in molecular diagnostics utilizes the Southern Blot approach to search for gene rearrangements or translocations useful in the diagnosis of lymphomas
42 Urothelial Carcinoma 55,000 cases/year ~12,500 deaths >95% of the bladder and upper urinary tract cancers in this country are UC s Squamous cell carcinomas of bladder: more common in Middle Eastern countries
43 Urothelial Carcinoma Cytology: High sensitivity in detection of HGTCC Greater difficulty in detecting LGTCC Challenging to differentiate normal urothelial cells from low grade tumor cells Most bladder cancers reoccur early recurrence often difficult to detect cytologically with cystoscopic specimens.
44 Urothelial Carcinoma: Testing Methods Brought *Antigen based methods BTA Stat, Immunocyt, NMP22, FDP Cytology Molecular genetic methods Telomerase, microsatellite analysis Flow cytometry/digital Image Analysis Cytogenetic methods FISH (Vysis, Inc. (UroVision)) multi color test that detects aneuploidy for chromosomes 3,7, 9p21, and 17 *not very effective in confirming the primary diagnosis of low grade urothelial carcinoma
45 Urothelial Carcinoma: Testing Method (Vysis) Brought Control Slides (Separate) 20X SSC NP-40 DAPI II DNA Probe Mixture CEP 3, CEP 7, LSI 9p21, CEP 17
46 Urovysion Intended Use Non invasive method Monitoring of tumor recurrence in conjunction with cystoscopy in patients previously diagnosed with bladder cancer.
47 FNA Applications Breast cancer: Mutated p53 found in 50% of all human cancers, including up to 80% of breast cancer and colon cancer The p53 protein normally suppresses cell growth, but when mutated, allows for uncontrolled cellular growth PCR based implications and current genomic microarrays with assess mutant p53
48 FNA Applications Pancreatic cancer: K ras mutations are seen in 90% of pancreatic carcinomas and up to 80% of cholangiocarcinomas Effusions: FISH analysis for chromosomes 3, 8, 10, and 12 are being used to determine hyperdiploidy for equivocal or atypical cells
49 FNA Applications K ras mutations Colorectal tumors: GI tumors with mutations in K ras have been shown to be more likely to reoccur. The proto oncogene recognized as mutated most commonly in endometrial carcinoma is K ras (10 30%).
50 IHC Versus Molecular Diagnostics Brought ISH and FISH: Greater sensitivity and specificity IHC: Faster Less expensive Allows pathologist to assess target gene expression along with other visible landmarks in the slide * Some labs use IHC as initial screening method, then confirm with ISH or FISH*
51 Summary Molecular testing analyzes tissue specific and tumor specific (mutation) targets. Genome, chromosome, and gene mutations are useful targets for diagnosis and detection of solid tumors. Immunohistochemical markers and FISH both have advantages and disadvantages when used separate. Using the two methods together increases sensitivity and specificity.
Special topics in tumor biochemistry oncogenes-and- tumour-suppressor-genes) Speaker: Prof. Jiunn-Jye Chuu E-Mail: firstname.lastname@example.org Genetic Basis of Cancer Cancer-causing mutations Disease of aging
CHAPTER 19 THE ORGANIZATION AND CONTROL OF EUKARYOTIC GENOMES Section D: The Molecular Biology of Cancer 1. Cancer results from genetic changes that affect the cell cycle 2. Oncogene proteins and faulty
Link full download:https://getbooksolutions.com/download/test-bank-for-robbinsand-cotran-pathologic-basis-of-disease-9th-edition-by-kumar Test Bank for Robbins and Cotran Pathologic Basis of Disease 9th
Early Embryonic Development Maternal effect gene products set the stage by controlling the expression of the first embryonic genes. 1. Transcription factors 2. Receptors 3. Regulatory proteins Maternal
Biochemistry of Cancer and Tumor Markers The term cancer applies to a group of diseases in which cells grow abnormally and form a malignant tumor. It is a long term multistage genetic process. The first
TUMOR MARKERS M.Shekarabi IUMS Definition Many cancers are associated with the abnormal production of some molecules l which h can be measured in plasma. These molecules are known as tumor markers. A good
Chapt. 18 Cancer Molecular Biology of Cancer Student Learning Outcomes: Describe cancer diseases in which cells no longer respond Describe how cancers come from genomic mutations (inherited or somatic)
Multistep nature of cancer development Phenotypic progression loss of control over cell growth/death (neoplasm) invasiveness (carcinoma) distal spread (metastatic tumor) Genetic progression multiple genetic
PATHOPHYSIOLOGY Name Chapter 9, Part 1: Biology of Cancer and Tumor Spread I. Cancer Characteristics and Terminology Neoplasm new growth, involves the overgrowth of tissue to form a neoplastic mass (tumor).
Mohammed El-Khateeb Tumor Genetics MGL-12 July 21 st 2013 台大農藝系遺傳學 601 20000 Chapter 22 slide 1 Cellular Basis of Cancer Cancer is a collection of diseases characterized by abnormal and uncontrolled growth
Bihong Zhao, M.D, Ph.D Department of Pathology 04-28-2009 Is tumor self or non-self? How are tumor antigens generated? What are they? How does immune system respond? Introduction Tumor Antigens/Categories
Tumor suppressor genes 1 D R. S H O S S E I N I - A S L What is a Tumor Suppressor Gene? 2 A tumor suppressor gene is a type of cancer gene that is created by loss-of function mutations. In contrast to
Neoplasia Dr Rodney Itaki Lecturer Anatomical Pathology Discipline University of Papua New Guinea School of Medicine & Health Sciences Division of Pathology General Considerations Overview: Neoplasia uncontrolled,
Lecture 8 Neoplasia II Dr. Nabila Hamdi MD, PhD ILOs Understand the definition of neoplasia. List the classification of neoplasia. Describe the general characters of benign tumors. Understand the nomenclature
American Society of Cytopathology Core Curriculum in Molecular Biology American Society of Cytopathology Core Curriculum in Molecular Biology Chapter 6 Fluorescence in situ Hybridization (FISH) Principles
Introduction to Genetics Table of contents Chromosome DNA Protein synthesis Mutation Genetic disorder Relationship between genes and cancer Genetic testing Technical concern 2 All living organisms consist
1 Cancer A. What is it? - A cancer is an uncontrolled, independent proliferation of robust, healthy cells. * In some the rate is fast; in others, slow; but in all cancers the cells never stop dividing.
Cancer The fundamental defect is unregulated cell division. Properties of Cancerous Cells Altered growth and proliferation Loss of growth factor dependence Loss of contact inhibition Immortalization Alterated
Quality in Control PD-L1 Analyte Control DR PD-L1_PI_v2 Product Codes: HCL019, HCL020 and HCL021 Contents PD-L1 Analyte Control DR 2 What is PD-L1? 3 The Role of PD-L1 in Cancer 3 PD-L1 Assessment 4 PD-L1
Cancer The fundamental defect is unregulated cell division. Properties of Cancerous Cells Altered growth and proliferation Loss of growth factor dependence Loss of contact inhibition Immortalization Alterated
396 Cancer Inheritance STEVEN A. FRANK Asingle inherited mutant gene may be enough to cause a very high cancer risk. Single-mutation cases have provided much insight into the genetic basis of carcinogenesis,
MEDICAL POLICY SUBJECT: URINARY TUMOR MARKERS FOR PAGE: 1 OF: 5 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including
Oncology 101 Cancer Basics What Will You Learn? What is Cancer and How Does It Develop? Cancer Diagnosis and Staging Cancer Treatment What is Cancer? Cancer is a group of more than 100 different diseases
142 8. Cell Cycle and Cancer NOTES CELL CYCLE G 0 state o Resting cells may re-enter the cell cycle Nondividing cells (skeletal and cardiac muscle, neurons) o Have left the cell cycle and cannot undergo
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
Chapter 18- Oncogenes, tumor suppressors & Cancer - Previously we have talked about cancer which is an uncontrolled cell proliferation and we have discussed about the definition of benign, malignant, metastasis
Colon Cancer and Hereditary Cancer Syndromes Gisela Keller Institute of Pathology Technische Universität München email@example.com Colon Cancer and Hereditary Cancer Syndromes epidemiology models
Dominant Acting Oncogenes Eugene E. Marcantonio, M.D. Ph.D. Oncogenes are altered forms of normal cellular genes called proto-oncogenes that are involved in pathways regulating cell growth, differentiation,
Medical Policy Genetic Testing for Colorectal Cancer Type: Medical Necessity and Investigational / Experimental Policy Specific Section: Laboratory/Pathology Original Policy Date: Effective Date: October
Genetics and Cancer Ch 20 Cancer is genetic Hereditary cancers Predisposition genes Ex. some forms of colon cancer Sporadic cancers ~90% of cancers Descendants of cancerous cells all cancerous (clonal)
Chapter 1 Cancer and sornat ic evolution 1.1 What is cancer? The development and healthy life of a human being requires the cooperation of more than ten million cells for the good of the organism. This
What All of Us Should Know About Cancer and Genetics Beth A. Pletcher, MD, FAAP, FACMG Associate Professor of Pediatrics UMDNJ- New Jersey Medical School Disclosures I have no relevant financial relationships
2/22/10 Cancer genetics Inside cancer web site http://www.insidecancer.org/ National Cancer Institute http://www.cancer.gov/cancerinfo/ An adult human has somewhere around one hundred trillion (10 14 )
Genetics of Oncology Ryan Allen Roy MD July 8, 2004 University of Tennessee CREOG Objectives Describe the clinical relevance of viral oncogenes Describe the role of aneuploidy in the pathogenesis of neoplasia
MOLECULAR BASIS OF ONCOGENESIS MUDr. Jiří Vachtenheim, CSc. 1 Cell processes which result also in cell cycle effects. Differentiation. Differentiated cells are usually in the G0 phase of the cell cycle.
Agro/Ansc/Bio/Gene/Hort 305 Fall, 2017 MEDICAL GENETICS AND CANCER Chpt 24, Genetics by Brooker (lecture outline) #17 INTRODUCTION - Our genes underlie every aspect of human health, both in function and
Part I An Introduction to Cancer 2 Chapter 1 Cancer: Descriptive Overview Cancer is a disease in which cells propagate uncontrollably. These cells can come from many different parts of the body and the
Histol Histopathol (1 999) 14: 269-277 http://www.ehu.es/histol-histopathol Histology and Histo pathology Invited Re vie W Molecular genetics of ovarian carcinomas J. Diebold Pathological Institute, Ludwig-Maximilians-University
Genomic instability Amin Mahpour 1 Some questions to ponder What is Genomic instability? What factors contribute to the genomic integrity? How we identify these aberrations? 2 PART I: MOLECULAR BIOLOGY
Introduction to Basic Oncology Cancer Cell AHS 102 Med Term Dr. Susie Turner 1/3/13 General Oncology Study of Tumors Neoplasms/Tumors Abnormal growth of new tissue Are either; Benign or Malignant Onc/o
Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Elizabeth H. Moore, MD Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Genomic testing has resulted in a paradigm shift in the
Questions about cancer What is cancer? Cancer Gil McVean, Department of Statistics, Oxford What causes unregulated cell growth? What regulates cell growth? What causes DNA damage? What are the steps in
Kavya Puchhalapalli CALS Honors Project Report Spring 2017 Studying The Role Of DNA Mismatch Repair In Brain Cancer Malignancy Abstract Malignant brain tumors including medulloblastomas and primitive neuroectodermal
MIT Biology Department 7.012: Introductory Biology - Fall 2004 Instructors: Professor Eric Lander, Professor Robert A. Weinberg, Dr. Claudette Gardel Friday 11/12/04 7.012 Quiz 3 Answers A > 85 B 72-84
Introduction to Cancer Bioinformatics and cancer biology Anthony Gitter Cancer Bioinformatics (BMI 826/CS 838) January 20, 2015 Why cancer bioinformatics? Devastating disease, no cure on the horizon Major
Chapter 3 Neoplasms Terminology Related to Neoplasms and Tumors Neoplasm New growth Tumor Swelling or neoplasm Leukemia Malignant disease of bone marrow Hematoma Bruise or contusion Classification of Neoplasms
Clinical Significance Of MSI, KRAS, & EGFR Pathway In Colorectal Carcinoma UCSF & Stanford Current Issues In Anatomic Pathology Introduction Microsatellite instability and mismatch repair protein deficiency
Overview of the core ideas in cancer research Paul Edwards Cancer Research UK Cambridge Institute and Department of Pathology, University of Cambridge This lecture Overview of the ideas that provide the
Genetics of Cancer Lecture 32 Cancer II rof. Bevin Engelward, MIT Biological Engineering Department Why Cancer Matters New Cancer Cases in 1997 Cancer Deaths in 1997 Genetics of Cancer: Today: What types
Anatomic Molecular Pathology: An Emerging Field Antonia R. Sepulveda M.D., Ph.D. University of Pennsylvania firstname.lastname@example.org 2008 ASIP Annual Meeting Anatomic pathology (U.S.) is a medical specialty
Chapter 8 DNA Replication, Binary Fission, and Mitosis World s tallest man Frederic J. Brown/AFP/Getty Images Copyright McGraw-Hill Education. All rights reserved. No reproduction or distribution without
microrna Presented for: Presented by: Date: 2 micrornas Non protein coding, endogenous RNAs of 21-22nt length Evolutionarily conserved Regulate gene expression by binding complementary regions at 3 regions
Solution Key - Practice Questions Question 1 a) A recent publication has shown that the fat stem cells (FSC) can act as bone stem cells to repair cavities in the skull, when transplanted into immuno-compromised
Gynecologic Malignancies Kristen D Starbuck 4/20/18 Outline Female Cancer Statistics Uterine Cancer Adnexal Cancer Cervical Cancer Vulvar Cancer Uterine Cancer Endometrial Cancer Uterine Sarcoma Endometrial
Clinical Medicine: Cancer Present State of Gene Diagnosis and Future Prospects JMAJ 45(3): 118 124, 2002 Eiichi TAHARA Chairman, Hiroshima Cancer Seminar Foundation Abstract: The entire base sequence of
COLORECTAL PATHWAY GROUP, MANCHESTER CANCER Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer January 2015 1 Background Mismatch repair (MMR) deficiency is seen in approximately
The Development of Lymphocytes: B Cell Development in the Bone Marrow & Peripheral Lymphoid Tissue Deborah A. Lebman, Ph.D. OBJECTIVES 1. To understand how ordered Ig gene rearrangements lead to the development
HALLMARKS OF CANCER - Together dictate the malignant phenotype. 1. Self-sufficiency in growth signals 2. Insensitivity to growth inhibitory signals 3. Evasion of cell death 4. Limitless replicative potential
Colonic polyps and colon cancer Andrew Macpherson Director of Gastroentology University of Bern Improtance of the problem of colon cancers - Epidemiology Lifetime risk 5% Incidence/10 5 /annum (US Detroit
C L L CLL Prepared by: Abd El-Hakeem Abd El-Rahman Abu Naser Ahmed Khamis Abu Warda Ahmed Mohammed Abu Ghaben Bassel Ziad Abu Warda Nedal Mostafa El-Nahhal Dr.Mansour Al-Yazji LEUKEMIA Leukemia is a form
Determination of the temporal pattern and importance of BALF1 expression in Epstein-Barr viral infection Melissa Mihelidakis May 6, 2004 7.340 Research Proposal Introduction Apoptosis, or programmed cell
INTRODUCTION TO PATHOLOGY The literal translation of the word pathology is the study (logos) of suffering (pathos). It is a discipline that bridges clinical practice and basic sciences. Pathology is concerned
Cell Division and Cancer By Dr. Carmen Rexach Physiology Mount San Antonio College The Cell Cycle Interphase: G 1, S, G 2, (G 0 ) Cell division and cytokinesis prophase metaphase anaphase telophase Interphase
The mutations that drive cancer Paul Edwards Department of Pathology and Cancer Research UK Cambridge Institute, University of Cambridge Previously on Cancer... hereditary predisposition Normal Cell Slightly
Template for Reporting Results of Biomarker Testing of Specimens From Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Version: CLLBiomarkers 22.214.171.124 Protocol Posting Date: June 2017
[Frontiers in Bioscience 3, d1148-1160, November 15, 1998] MOLECULAR PATHOBIOLOGY OF PANCREATIC ADENOCARCINOMA Shamlal Mangray and Thomas C King Department of Pathology and Laboratory Medicine, Brown University
Your Guide to the Breast Cancer Pathology Report Key Questions Here are important questions to be sure you understand, with your doctor s help: Your Guide to the Breast Cancer Pathology Report 1. Is this
Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer Start date: May 2015 Review date: April 2018 1 Background Mismatch repair (MMR) deficiency is seen in approximately 15%
Genetics and Cancer ERICA L SILVER, MS, LCGC GENETIC COUNSELOR Genetics 101 Transcription vs Translation 1 Carcinogenesis and Genetics Normal cell First mutation First mutation Second mutation Second mutation
Diseases of the breast (2 of 2) Breast cancer Epidemiology & etiology The most common type of cancer & the 2 nd most common cause of cancer death in women 1 of 8 women in USA Affects 7% of women Peak at